R. Thimme

R. Thimme

Auto-generated profile, based on publicly available information

R. Thimme

Medizinische Universitätsklinik Freiburg, Abteilung Innere Medizin II, Hugstetter Strasse 55, 79106 Freiburg

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2012 in Zeitschrift für Gastroenterologie
Verified
Journal Article
Closed access
TFT. Flecken
T. Flecken
NSN. Schmidt
N. Schmidt
HSH. C. Spangenberg
H. C. Spangenberg
RTR. Thimme
R. Thimme
Das hepatozelluläre Karzinom (HCC; vom engl. hepatocellular carcinoma) ist der fünfthäufigste maligne Tumor weltweit mit steigender Inzidenz. Der klinische Verlauf der Erkrankung ist durch die häufig zugrunde liegende Leberzirrhose, die Tumorgröße zum Zeitpunkt der Diagnose sowie die zur Verfügung stehenden Therapien limitiert. In den letzten Jahren wurden große Fortschritte im Verständnis der Immunbiologie des HCCs erzielt. In diesem Artikel sollen aktuelle Erkenntnisse über die Biologie des HCCs, über die Bedeutung chronischer Entzündungen bei der Karzinogenese und über die Rolle der tumorspezifischen Immunantworten dargestellt werden. Außerdem werden mögliche neue immunbasierte Therapieformen vorgestellt, die in Zukunft das Spektrum der Therapien beim HCC erweitern könnten. Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide with an increasing incidence. The clinical outcome is influenced by the underlying liver cirrhosis, the size of the tumour at the time of diagnosis and the few therapeutic options currently available. In recent years there has been a lot of progress in the understanding of HCC immunobiology. This review summarizes our current knowledge of HCC biology, the role of chronic inflammation in carcinogenesis and the role of tumour-specific immune responses. Furthermore, we will present potentially new, immune-based therapies that might open up new avenues for the treatment of HCC.

2 January 2004 in Zeitschrift für Gastroenterologie
Verified
Journal Article
Closed access
EPE. Panther
E. Panther
HSH. C. Spangenberg
H. C. Spangenberg
CNC. Neumann-Haefelin
C. Neumann-Haefelin
KRK. Rösler
K. Rösler
HBH. E. Blum
H. E. Blum
RTR. Thimme
R. Thimme
Infektionen mit dem Hepatitis-B- (HBV) und Hepatitis-C-Virus (HCV) gehören weltweit zu den häufigsten Ursachen der chronischen Hepatitis mit dem Risiko der Entwicklung einer Leberzirrhose und des hepatozellulären Karzinoms. Die grundlegenden Mechanismen, die für die Viruselimination oder -persistenz verantwortlich sind, sind noch weit gehend ungeklärt. Die Immunpathogenese der HBV- und HCV-Infektion wird wesentlich durch die virusspezifische T-Zell-Antwort bestimmt. Während der akuten Phase findet man eine starke und multispezifische, d. h. gegen verschiedene Epitope des Virus gerichtete T-Zellantwort, die zur Elimination des Virus führen kann. Gelingt es dem Organismus nicht, das Virus zu eliminieren, können die T-Zellen in der chronischen Phase der Erkrankung wesentlich zur Entstehung der entzündlichen Lebererkrankung beitragen. In dieser Übersichtsarbeit werden die aktuellen Konzepte über die Rolle der virusspezifischen T-Zellantwort bei der akuten und chronischen Hepatitis-B- und -C-Virusinfektion zusammenfassend dargestellt. Infections with hepatitis B (HBV) and hepatitis C virus (HCV) are worldwide one of the most frequent causes for chronic liver disease, liver cirrhosis and hepatocellular carcinoma. The mechanisms responsible for the elimination or the persistence of the virus are not well understood. The immunopathogenesis of HBV and HCV infection is primarily mediated by virus specific CD4+- and CD8+-T-cells. During acute infection a strong and multispecific T-cell response against different viral epitopes can be detected and is associated with the clearance of the virus. In case of viral persistence virus specific T-cells contribute to liver inflammation. In this article we summarize the current concepts about the role of the virus specific T-cell response in acute and chronic HBV and HCV infection.

9 January 2012 in Zeitschrift für Gastroenterologie
Verified
Journal Article
Closed access
DBD Bettinger
D Bettinger
MSM Schultheiß
M Schultheiß
EKE Knüppel
E Knüppel
RTR Thimme
R Thimme
HBHe Blum
He Blum
HSHc Spangenberg
Hc Spangenberg
Aims: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide with an increasing incidence. For patients with advanced HCC Sorafenib is the treatment of choice since the SHARP study showed a survival benefit however daily clinical experience suggests that Sorafenib is much less effective than described in the SHARP study. Methods: Retrospectively, we analyzed 112 patients with advanced HCC treated with Sorafenib comparing overall survival (OS), time to progression (TTP) and frequency of adverse events of our study cohort with those of the SHARP and Asia – Pacific study. Patients receiving transarterial chemoembolisation or local ablative therapies in combination with Sorafenib were excluded from the study. Radiologic treatment response was evaluated using the modified RECIST 1.1 criteria. Results: The median duration of Sorafenib treatment was 3 months (0.4–45 months). 77 patients (68.8%) stopped Sorafenib as a result of adverse events.They are comparable to those of the SHARP and Asia- Pacific study with 32.1% of the patients having diarrhea, 15.2% hand-foot-syndrome and 13.4% having fatigue. Weight loss (8%), bleeding (3.6%), nausea and vomiting (5.4%) were less common adverse events. The median OS and TTP in our patients were 9.6 months and 3.9 months respectively. In 75 patients treatment response was evaluated using imaging studies. 24 patients (32.4%) had stable disease whereas in 50 patients (67.6%) disease progression was observed. None of our patients had complete or partial remission.Conclusions: We were able to reproduce the data from the SHARP study concerning OS and TTP. The distribution of adverse events was comparable to those in the SHARP and Asia- Pacific study. With regard to radiologic treatment response our patients reached stable disease less frequent than those in the SHARP and Asia- Pacific study probably as a result of our unselected study cohort. But concerning the endpoints our patients showed similar OS and TTP. Literatur: 1. Jemal A.,Bray F.,Center M.M.,Ferlay J.,Ward E.Forman D. (2011), Global cancer statistics. CA Cancer J Clin, 61: p. 69-90. 2. Llovet J.M.,Ricci S.,Mazzaferro V.,Hilgard P.,Gane E.,Blanc J.F.,de Oliveira A.C.,Santoro A.,Raoul J.L.,Forner A.,Schwartz M.,Porta C.,Zeuzem S.,Bolondi L.,Greten T.F.,Galle P.R.,Seitz J.F.,Borbath I.,Haussinger D.,Giannaris T.,Shan M.,Moscovici M.,Voliotis D.Bruix J. (2008), Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359: p. 378-90. 3. Cheng A.L.,Kang Y.K.,Chen Z.,Tsao C.J.,Qin S.,Kim J.S.,Luo R.,Feng J.,Ye S.,Yang T.S.,Xu J.,Sun Y.,Liang H.,Liu J.,Wang J.,Tak W.Y.,Pan H.,Burock K.,Zou J.,Voliotis D.Guan Z. (2009), Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol, 10: p. 25-34. 4. Wilhelm S.M.,Carter C.,Tang L.,Wilkie D.,McNabola A.,Rong H.,Chen C.,Zhang X.,Vincent P.,McHugh M.,Cao Y.,Shujath J.,Gawlak S.,Eveleigh D.,Rowley B.,Liu L.,Adnane L.,Lynch M.,Auclair D.,Taylor I.,Gedrich R.,Voznesensky A.,Riedl B.,Post L.E.,Bollag G.Trail P.A. (2004), BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 64: p. 7099-109. 5. Chang Y.S.,Adnane J.,Trail P.A.,Levy J.,Henderson A.,Xue D.,Bortolon E.,Ichetovkin M.,Chen C.,McNabola A.,Wilkie D.,Carter C.A.,Taylor I.C.,Lynch M.Wilhelm S. (2007), Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol, 59: p. 561-74.

28 September 2009 in Zeitschrift für Gastroenterologie
Verified
Journal Article
Closed access
CNC Neumann-Haefelin
C Neumann-Haefelin
JTJ Timm
J Timm
JSJ Schmidt
J Schmidt
KFK Fitzmaurice
K Fitzmaurice
SMS McKiernan
S McKiernan
RTR Thimme
R Thimme
Introduction: HLA-B27 is associated with protection in HIV and hepatitis C virus (HCV) infection. This protective role is linked to single immunodominant HLA-B27 restricted CD8+ T cell epitopes in both infections. Aim: In order to define the relative contribution of a specific HLA-B27 restricted epitope to the natural course of HCV infection, we compared the biological impact of the highly conserved HCV genotype 1 epitope, for which the protective role has been described, with the corresponding region in genotype 3 that differs in its sequence by three amino acid residues. Methods: The epitope-specific CD8+ T cell response as well as viral sequences were analyzed in HLA-B27+ patients with acute or chronic HCV genotype 1 or 3a infection. In addition, the HLA-B27 frequency was determined in a large cohort of patients chronically infected with HCV genotype 1 or 3a. Results: The genotype 3a peptide is not recognized by CD8+ T cells specific for the genotype 1 peptide. Furthermore, patients with acute or chronic infection with HCV genotype 3a did not mount T cell responses to this epitope region, and their autologous viral sequences showed no evidence of T cell pressure. Finally, we found a significantly higher frequency of HLA-B27 positivity in patients with chronic HCV genotype 3a infection compared to genotype 1 infection, indicating that there is no protection in HCV genotype 3 infection. Conclusion: Our data indicate that the protective effect of HLA-B27 is limited to HCV genotype 1 infection and does not expand to other genotypes such as genotype 3a. This can be explained by inter-genotype sequence diversity leading to the loss of the immunodominant HLA-B27 epitope in viral strains other than genotype 1. Our results demonstrate the central role of a single HLA-B27 restricted epitope specific CD8+ T cell response in mediating protection in HCV genotype 1 infection and the difficulty to develop T cell based vaccines across the boundary of genotypes.

9 June 2010 in DMW - Deutsche Medizinische Wochenschrift
Verified
Journal Article
Closed access
PDF file
RTR Thimme
R Thimme
HSH Spangenberg
H Spangenberg
HBH Blum
H Blum
Was ist neu? Hepatitis B: Aktuelle europäische Therapieempfehlungen. Hepatitis C: Neue antivirale Substanzen in Kombination mit Standardtherapie, IL28B-Polymorphismus als Prognoseparameter. Cholestatische Hepatopathien: Neue Einblicke in die Pathogenese. Leberzirrhose – Komplikationen: Senkung des hepatischen Venenverschlussdrucks durch Carvedilol. Hepatozelluläres Karzinom: Prognoseabschätzung mit MicroRNA. Cholangiozelluläres Karzinom: Standardtherapie mit Gemcitabin und Cisplatin.

13 January 2011 in Zeitschrift für Gastroenterologie
Verified
Journal Article
Closed access
DGD Grimm
D Grimm
CNC Neumann-Haefelin
C Neumann-Haefelin
NKN Kersting
N Kersting
HBHe Blum
He Blum
RTR Thimme
R Thimme
Single nucleotide polymorphisms (SNP) in the IL28B gene region on chromosome 19 are important in predicting natural course and therapy outcome in chronic hepatitis C virus (HCV) infection. This finding might be of major importance in clinical treatment decision-making in the near future. Until now, the mechanisms behind this observation are unknown. We could show previously that CD8+ T cells play a pivotal role in HCV pathogenesis and viral clearance. Therefore, we asked whether the IL28B genotype is mechanistically linked to HCV-specific CD8+ T cell responses. We analyzed CD8+ T cell responses in a well-characterized cohort (n=20) of HCV patients using overlapping peptides in a matrix set-up Elispot assay and confirmed positive responses by intracellular IFN-γ staining using individual peptides. In addition, we determined the SNP rs12979860 genotype. We could show that for SNP rs12979860, there are no significant differences in the number of epitopes recognized by HCV-specific T cells or the T cell frequency of individuals with the favorable genotype C/C compared to genotypes C/T or T/T. Importantly, this holds true for the intrahepatic compartment as well as for peripheral blood. In agreements with previous findings we could show that in the majority of patients with the favorable genotype C/C antiviral therapy with pegylated IFN was successful. This finding suggests that there is no mechanistic link between the rs12979860 genotype and the adaptive HCV-specific CD8+ T cell response.